|
| 08 April 2024 |
|
|
|
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Patent submission for Optimer® binders in cosmetic products
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications in fast moving consumer goods generated as part of its partnership with Unilever.
The patent was submitted on 28 March 2024. Submission of this patent application reinforces the ongoing commercial protection of Aptamer Group's leading technology position in the development of high-performance binders.
Aptamer Group developed the binders as part of a fee-for-service project and has continued to support Unilever in validating the functionality of the binders both in-house at Aptamer Group and within Unilever's own labs. Submission of the patent at this stage establishes a 'priority date' for the binder sequences, giving Aptamer Group precedence for the protection of the intellectual property while allowing commercial negotiations to continue.
Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "The submission of this patent is an important milestone for Aptamer Group and supports the next stages of commercial advancement with Unilever. We are really pleased with the work performed by our scientists and those at Unilever over the past few months to demonstrate the use of these Optimer binders and their suitability for application in fast moving consumer goods. We will continue to work closely with the team at Unilever to support their use of the binders in this exciting new application."
Dr Samantha Samaras, Senior Vice President of R&D at Unilever, said: "Over the past 12 months we have been working with the excellent team at Aptamer Group to discover, develop and exploit their Optimer binders for cosmetic applications. We look forward to continued collaboration in this exciting applications space."
- ENDS -
For further information, please contact:
| Aptamer Group plc Steve Hull | +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes | +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
